<?xml version='1.0' encoding='utf-8'?>
<document id="31594667"><sentence text="Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C."><entity charOffset="33-41" id="DDI-PubMed.31594667.s1.e0" text="elbasvir" /><entity charOffset="42-53" id="DDI-PubMed.31594667.s1.e1" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.31594667.s1.e0" e2="DDI-PubMed.31594667.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31594667.s1.e0" e2="DDI-PubMed.31594667.s1.e1" /></sentence><sentence text="The assessment of drug-drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC)" /><sentence text=" This study aims to evaluate DDI before and during elbasvir/grazoprevir (EBR/GZR) treatment"><entity charOffset="60-71" id="DDI-PubMed.31594667.s3.e0" text="grazoprevir" /></sentence><sentence text="" /><sentence text="CHC patients who treated with EBR/GZR in five hospitals were enrolled" /><sentence text=" The patients' demographic data, comorbidities, concomitant medications taken before and during EBR/GZR were recorded" /><sentence text=" DDI was evaluated using a tool from the HEP Drug Interactions (www" /><sentence text="hep-druginteractions" /><sentence text="org) website" /><sentence text=" In addition to the evaluation of DDI for EBR/GZR, the virtual DDI of ledipasvir/sofosbuvir (LDV/SOF), sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) were evaluated"><entity charOffset="70-80" id="DDI-PubMed.31594667.s10.e0" text="ledipasvir" /><entity charOffset="81-91" id="DDI-PubMed.31594667.s10.e1" text="sofosbuvir" /><entity charOffset="103-113" id="DDI-PubMed.31594667.s10.e2" text="sofosbuvir" /><entity charOffset="114-125" id="DDI-PubMed.31594667.s10.e3" text="velpatasvir" /><entity charOffset="127-130" id="DDI-PubMed.31594667.s10.e4" text="SOF" /><entity charOffset="131-134" id="DDI-PubMed.31594667.s10.e5" text="VEL" /><entity charOffset="140-151" id="DDI-PubMed.31594667.s10.e6" text="glecaprevir" /><entity charOffset="152-164" id="DDI-PubMed.31594667.s10.e7" text="pibrentasvir" /><entity charOffset="166-169" id="DDI-PubMed.31594667.s10.e8" text="GLE" /><entity charOffset="170-173" id="DDI-PubMed.31594667.s10.e9" text="PIB" /><entity charOffset="97-99" id="DDI-PubMed.31594667.s10.e10" text="SOF" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e10" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e0" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e10" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e1" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e10" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e10" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e2" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e3" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e4" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e5" e2="DDI-PubMed.31594667.s10.e5" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e5" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e5" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e5" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e5" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e6" e2="DDI-PubMed.31594667.s10.e6" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e6" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e6" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e6" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e7" e2="DDI-PubMed.31594667.s10.e7" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e7" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e7" e2="DDI-PubMed.31594667.s10.e9" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e8" e2="DDI-PubMed.31594667.s10.e8" /><pair ddi="false" e1="DDI-PubMed.31594667.s10.e8" e2="DDI-PubMed.31594667.s10.e9" /></sentence><sentence text=" Degrees of DDI were classified as &quot;do not co-administer&quot;, &quot;potential interaction&quot;, and &quot;potentially weak interaction&quot;" /><sentence text="" /><sentence text="A total of 460 patients were enrolled" /><sentence text=" At baseline, 80" /><sentence text="1% of patients had one or more comorbidities and 72" /><sentence text="8% took one or more medications" /><sentence text=" Cardiovascular diseases (43" /><sentence text="9%), gastrointestinal diseases (37" /><sentence text="4%), and metabolic diseases (36" /><sentence text="7%) were the three most common comorbidities" /><sentence text=" The prevalence of DDI before EBR/GZR treatment was 12" /><sentence text="8% (59 patients)" /><sentence text=" Among the same population, the prevalence of virtual DDI of SOF/VEL, GLE/PIB, and LDV/SOF were 38"><entity charOffset="61-63" id="DDI-PubMed.31594667.s23.e0" text="SOF" /><entity charOffset="87-89" id="DDI-PubMed.31594667.s23.e1" text="SOF" /><entity charOffset="65-67" id="DDI-PubMed.31594667.s23.e2" text="VEL" /><entity charOffset="70-72" id="DDI-PubMed.31594667.s23.e3" text="GLE" /><entity charOffset="74-76" id="DDI-PubMed.31594667.s23.e4" text="PIB" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e0" e2="DDI-PubMed.31594667.s23.e0" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e0" e2="DDI-PubMed.31594667.s23.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e0" e2="DDI-PubMed.31594667.s23.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e0" e2="DDI-PubMed.31594667.s23.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e0" e2="DDI-PubMed.31594667.s23.e1" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e2" e2="DDI-PubMed.31594667.s23.e2" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e2" e2="DDI-PubMed.31594667.s23.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e2" e2="DDI-PubMed.31594667.s23.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e2" e2="DDI-PubMed.31594667.s23.e1" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e3" e2="DDI-PubMed.31594667.s23.e3" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e3" e2="DDI-PubMed.31594667.s23.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e3" e2="DDI-PubMed.31594667.s23.e1" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e4" e2="DDI-PubMed.31594667.s23.e4" /><pair ddi="false" e1="DDI-PubMed.31594667.s23.e4" e2="DDI-PubMed.31594667.s23.e1" /></sentence><sentence text="5% (179 patients), 48" /><sentence text="8% (220 patients), and 57" /><sentence text="0% (262 patients), respectively" /><sentence text=" During EBR/GZR treatment, 167 patients (36" /><sentence text="3%) took newly prescribed medications" /><sentence text=" One patient (0" /><sentence text="2%) and seven patients (1/5%) exhibited do-not-co-administer and potential interaction with EBR/GZR, respectively" /><sentence text="" /><sentence text="DDI was limited in treatment with EBR/GZR" /><sentence text=" DDI can occur upon the administering of a new medication during antiviral treatment and attention should be paid to it" /><sentence text="" /><sentence text="NCT03706222" /><sentence text="" /></document>